Результаты поиска

Pan-Genome Analysis of Oral Bacterial Pathogens to Predict a Potential Novel Multi-Epitopes Vaccine Candidate.

Porphyromonas gingivalis is a Gram-negative anaerobic bacterium, mainly present in the oral cavity and causes periodontal infections. Currently, no licensed vaccine is available against P. gingivalis and other oral bacterial pathogens. To develop a vaccine against P. gingivalis, herein, we applied a bacterial pan-genome analysis (BPGA) on the bacterial genomes that retrieved a total number of 4908 core proteins, which were further utilized for the identification of good vaccine candidates. After several vaccine candidacy analyses, three proteins, namely lytic transglycosylase domain-containing

Caution needed in using oral polio vaccine beyond the cold chain: vaccine vial monitors may be unreliable at high temperatures.

BACKGROUND & OBJECTIVES: Stabilized live attenuated oral polio vaccine (OPV) is used to immunize children up to the age of five years to prevent poliomyelitis. It is strongly advised that the cold-chain should be maintained until the vaccine is administered. It is assumed, that vaccine vial monitors (VVMs) are reliable at all temperatures. VVMs are tested at 37°C and it is assumed that the labels reach discard point before vaccine potency drops to >0.6 log10. This study was undertaken to see if VVMs were reliable when exposed to high temperatures as can occur in field conditions in India. MET…

Разработка эффективного процесса производства вакцины от ветеринарных бешенств на линии птичьей подвески AGE1.CR.pIX.

ЦЕЛЬ: Для наиболее эффективного сокращения и ликвидации бешенства также предлагается провести массовую вакцинацию собак в качестве важного резервуара бешенства. Однако для борьбы с этим заболеванием в зоонотических районах необходимо обеспечить минимальный охват на уровне 70%. Во многих развивающихся странах уровень вакцинации собак по-прежнему опасно низок из-за экономических трудностей и высокой текучести собачьей популяции. Совершенствование процессов производства вакцин может способствовать снижению издержек и сокращению поставок. В ходе этой работы мы изучили и оптимизировали репликацию и

Совпадение в аннотации оригинала
BACKGROUND: Mass vaccination of dogs as important rabies reservoir is proposed to most effectively reduce and eliminate rabies also in human … o alleviate cost and supply limitations. In this work, we studied and optimized the replication and vaccine potency of PV rabies virus strain in the muscovy-duck derived AGE1.CR and AGE1.CR.pIX suspension cell lines. RESULTS: The BHK-21-adapted PV rabies virus strain replicated efficiently in the avian cell lines without requirement for prior passaging. CR.pIX w …

Preparation and evaluation of a monovalent foot and mouth disease vaccine as a rapid response to the emerging serotype SAT1 in Egypt.

The recent emergence of foot and mouth disease virus (FMDV) serotype SAT1 in Egypt necessitated the development of a specific vaccine direct … y characteristics. The vaccine was formulated as a double oil emulsion using Montanide ISA 206. The vaccine potency was assessed in guinea pigs through determination of the protective dose (GPPD50) following challenge with virulent guinea pig adapted virus that revealed satisfactory protective potency. The humoral immune response induced by such vaccine was subse …

A mucosal adjuvant for the inactivated poliovirus vaccine.

The eradication of poliovirus from the majority of the world has been achieved through the use of two vaccines: the inactivated poliovirus vaccine (IPV) and the live-attenuated oral poliovirus vaccine (OPV). Both vaccines are effective at preventing paralytic poliomyelitis, however, they also have significant differences. Most importantly for this work is the risk of revertant virus from OPV, the greater cost of IPV, and the low mucosal immunity induced by IPV. We and others have previously described the use of an alphavirus-based adjuvant that can induce a mucosal immune response to a co-admi

[The antidiphtheria and antitetanus immunities of children of the Maritime Territory after the use of adsorbed DTP vaccine and adsorbed DT-m anatoxin].

The state of collective immunity to diphtheria and tetanus in children of preschool age, depending on the kind of vaccine preparation used for immunization, was studied. The immunological potency of adsorbed DPT vaccine (i.e. its capacity of forming prolonged and stable basic immunity) was shown to be higher in comparison with the potency of adsorbed DT toxoid with reduced antigen content (DT-R). The study revealed that in all groups of children the level of antitetanus immunity was higher than the level of antidiphtheria immunity, and 3 years later its decrease was less pronounced. A stricter

Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates.

Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical disease endpoint efficacy studies. However, ZIKV is still circulating at low levels in some areas and is likely to re-emerge in naïve populations or in sites of prior epide

Reduction of influenza A(H3N2)-associated symptoms by influenza vaccination in school aged-children during the 2014-2015 winter season dominated by mismatched H3N2 viruses.

BACKGROUND: Little is known about the vaccine effectiveness (VE) in attenuating the influenza-associated symptoms in children during the 2014-2015 influenza season in Beijing, China, in which there was a mismatch between the vaccine and circulating strain. METHODS: This study included 210 laboratory-confirmed influenza cases among children, who were enrolled in 2014, from November 1 to December 31. Standard demographic information and clinical symptoms were recorded. Influenza vaccination was confirmed via a vaccination registry. Univariate and multivariate analyses were used to estimate the

Biophysical virus particle specific characterization to sharpen the definition of virus stability.

Vaccine thermostability is key to successful global immunization programs as it may have a significant impact on the continuous cold-chain maintenance logistics, as well as affect vaccine potency. Modern biological and biophysical techniques were combined to in-depth characterize the thermostability of a formulated rabies virus (RABV) in terms of antigenic and genomic titer, virus particle count and aggregation state. Tunable resistive pulse sensing (TRPS) and nanoparticle tracking analysis (NTA) were used to count virus particles while simultaneously determining their size distribution. RABV …

Pre-immunization and post-exposure treatment with inactivated rabies vaccine of chick embryo cell culture origin (CEC).

Routine laboratory assay revealed that the potency of concentrated rabies vaccine of chick embryo cell culture (CEC) origin was in the same level compared with suckling mouse brain (SMB) vaccine. Over one hundred persons received two doses of CEC vaccine at an interval of one week and produced high level of neutralizing antibody against rabies virus. The monkeys experimentally infected with street rabies virus were satisfactorily protected by subcutaneous inoculation with CEC vaccine one hour after exposure. Eight persons bitten by dogs known to have rabies or suspected of it, survived after p

[Analysis of determination of rabies virus neutralizing antibody titres in the sera of vaccinated humans.].

INTRODUCTION: Rabies is an infectious disease that is always fatal following the onset of clinical symptoms. The only way to prevent the cases of rabies in humans is timely carried out the rabies post-exposure prophylaxis in accordance with the recommended schedule. OBJECTIVES: The aim of the study was to characterize the level of immune response in persons that received a post-exposure prophylaxis against rabies, to consider the role of the factors of the formation immune responses to rabies vaccines. MATERIAL AND METHODS: In the laboratory of viral vaccines of the Scientific Centre for Exp

Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.

The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the anthrax vaccine adsorbed (AVA) (Emergent BioSolutions Inc., Lansing, MI) bulk drug substance adjuvanted with the immunostimulatory oligodeoxynucleotide (ODN) compound, CPG 7909. The addition of CPG 7909 to AVA enhances both the magnitude and the kinetics of antibody responses in animals and human subjects, making AV7909 a suitable next-generation vaccine for use in a PEP setting. Emergent has produced a thermostable (lyoph

Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.

Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain o

Adjuvant effect of saponin in an oil-based monovalent (serotype O) foot-and-mouth disease virus vaccine on the antibody response in guinea pigs and cattle.

To enhance the potency of a foot-and-mouth disease (FMD) vaccine, saponin was included in the vaccine formula. In this study, the combined e … levels (p < 0.005) than 5 µg of 146S without saponin, suggesting that it can be used to improve FMD vaccine potency in susceptible animals. No adverse effects were observed in vaccinated cattle or guinea pigs.

Development of a Clinically Viable Heroin Vaccine.

Heroin is a highly abused opioid and incurs a significant detriment to society worldwide. In an effort to expand the limited pharmacotherapy options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive evaluation of hapten structure, carrier protein, adjuvant and dosing. Immunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin "immunoantagonism", reducing heroin potency by >15-fold. Moreover, the vaccine effects proved to be durable, persisting for over eigh

[Seasonal variations in the formation of virus-neutralizing antibodies in cattle after vaccination against foot-and-mouth disease].

The GDR in 1977 had been the first country to introduce a laboratory method for potency testing of FMD vaccines on the basis of secured correlations between titres of virus-neutralising serum antibodies of immunised cattle, on the one hand, and their probit-transformed protection against FMD, on the other. This is now the only state-registered method for potency testing. The method has ever since worked well all over the place. An evaluation of results obtained between 1982 and 1988 revealed seasonal variations of anti-FMD immunogenesis in cattle. FMD immunisations from February to July proved

Integrated Analytical Techniques to Investigate the Effect of the Freezing/Thawing Cycles on the Non-replicating Recombinant Chimpanzee Adenovirus Viral Vector COVID-19 Vaccine.

The chimpanzee adenovirus-vectored vaccine developed by the University of Oxford (ChAdOx1 nCoV-19) showed good stability when stored in refrigerator. However, the vaccine manufacturer prefers its transportation in frozen condition. Data regarding the stability of the vaccine after exposure to repeated freezing processes have not been explored yet. In the present study, different batches were exposed to 3 repeated freezing/thawing cycles. An orthogonal testing using various techniques was employed to assess any induced changes in the properties of the vaccine in comparison with control samples.

Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation.

By the use of continuous-flow zonal ultracentrifugation, a highly purified, inactivated tick-borne encephalitis (TBE) virus vaccine was prepared tht contained almost exclusively TBE virus particles. The purity of this preparation was 90- to 100-fold higher than that of a previously used partially purified vaccine. A mean protein content of 3-5 microgram/ml in the final vaccine represents 20 mouse protective doses50 in a mouse challenge potency test. This high degree of purity resulted in a strong reduction of side reactions observed with the less purified vaccine.

Expression of Concern for Elevated WTAP promotes hyperinflammation by increasing m6A modification in inflammatory disease models.

The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale and pace. As a result, current COVID-19 vaccination regimens comprise diverse vaccine modalities, immunogen combinations, and dosing intervals. Here, we compare vaccine-specific antibody and memory B cell responses following two-dose mRNA, single-dose Ad26.COV.2S, and two-dose ChAdOx1, or combination ChAdOx1/mRNA vaccination. Plasma-neutralizing activity, as well as the magnitude, clonal composition, and antibody maturation of the RBD-specific memory B cell c

An mRNA vaccine against rabies provides strong and durable protection in mice.

INTRODUCTION: Rabies is a serious public health problem worldwide for which an effective treatment method is lacking but can be prevented by … s of 1 μg RV021 provided full protection against challenge with CVS of 30~60-fold lethal dose, 50%. Vaccine potency testing (according to the National Institutes of Health) in vivo revealed that the potency of RV021 at 15 μg/dose was 7.5 IU/dose, which is substantially higher than the standard for lot release of rabies vaccines for current human use. CONCLUSION: …